A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226

被引：0
|
作者：
Mehta, Rita S.
Barlow, William E.
Albain, Kathy S.
Vandenberg, Ted A.
Dakhil, Shakher R.
Tirumali, Nagendra L.
Lew, Danika L.
Hayes, Daniel F.
Gralow, Julie R.
Linden, Hannah M.
Livingston, Robert B.
Hortobagyi, Gabriel N.
机构：
[1] UCIMC, Orange, CA USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Wichita Community Clin Oncol, Wichita, KS USA
[6] Northwest CCOP Northwest, Portland, OR USA
[7] Univ Michigan, Ann Arbor, MI 48109 USA
[8] Puget Sound Canc Consortium, Seattle, WA USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Univ Arizona, Arizona Canc, Tucson, AZ USA
[11] MD Anderson, Houston, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226
    Mehta, R. S.
    Barlow, W. E.
    Albam, K. S.
    Vandenberg, T.
    Dakhil, S. R.
    Tirumali, N. R.
    Lew, D. L.
    Hayes, D. F.
    Gralow, J. R.
    Livingston, R. B.
    Hortobagyi, G. N.
    CANCER RESEARCH, 2011, 71
  • [2] Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226
    Hertz, Daniel L.
    Barlow, William E.
    Kidwell, Kelley M.
    Albain, Kathy S.
    Vandenberg, Ted A.
    Dakhil, Shaker R.
    Tirumali, Nagendra R.
    Livingston, Robert B.
    Gralow, Julie
    Hayes, Daniel F.
    Hortobagyi, Gabriel N.
    Mehta, Rita S.
    Rae, James M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (06) : 1134 - 1141
  • [3] Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer
    Carlson, R. W.
    O'Neill, A.
    Vidaurre, T.
    Gomez, H. L.
    Badve, S.
    Sledge, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
    Bergh, Jonas
    Jonsson, Per-Ebbe
    Lidbrink, Elisabet Kerstin
    Trudeau, Maureen
    Eiermann, Wolfgang
    Brattstrom, Daniel
    Lindemann, Justin P. O.
    Wiklund, Fredrik
    Henriksson, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1919 - 1925
  • [5] Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women
    Vergote, I
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S57 - S58
  • [6] Anastrozole versus tamoxifen as first-line therapy for postmenopausal advanced breast cancer
    Bergmann, L
    STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (05) : 273 - 274
  • [7] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Liao, Weiting
    Huang, Jiaxing
    Wu, Qiuji
    Wen, Feng
    Zhang, Nan
    Zhou, Kexun
    Bai, Liangliang
    Li, Qiu
    BREAST CANCER, 2020, 27 (03) : 399 - 404
  • [8] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Weiting Liao
    Jiaxing Huang
    Qiuji Wu
    Feng Wen
    Nan Zhang
    Kexun Zhou
    Liangliang Bai
    Qiu Li
    Breast Cancer, 2020, 27 : 399 - 404
  • [9] Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II 'FIRST' study
    Robertson, John F. R.
    Llombart-Cussac, Antonio
    Feltl, David
    Dewar, John
    Jasiowka, Marek
    Hewson, Nicola
    Rukazenkov, Yuri
    Ellis, Matthew J.
    CANCER RESEARCH, 2015, 75
  • [10] Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Ini
    Somlo, George
    Barlow, William
    Moore, Halle
    Gralow, Julie
    Schott, Anne
    Hayes, Daniel
    Kuhn, Peter
    Hicks, James
    Lew, Danika
    Tripathy, Debu
    Hortobagyl, Gabriel
    CANCER RESEARCH, 2015, 75
12345